Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
October 20, 2021Targovax ASA appoints Dr. Erik Digman Wiklund as new CEO
October 19, 2021Targovax to present at upcoming conferences
October 6, 2021Targovax ASA: Two abstracts accepted at the SITC Congress
October 3, 2021Targovax ASA issues options to new member of management